Last reviewed · How we verify
Quadrivalent Influenza mRNA Vaccine MRT5421
Quadrivalent Influenza mRNA Vaccine MRT5421 is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 1 development.
At a glance
| Generic name | Quadrivalent Influenza mRNA Vaccine MRT5421 |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quadrivalent Influenza mRNA Vaccine MRT5421 CI brief — competitive landscape report
- Quadrivalent Influenza mRNA Vaccine MRT5421 updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Quadrivalent Influenza mRNA Vaccine MRT5421
What is Quadrivalent Influenza mRNA Vaccine MRT5421?
Quadrivalent Influenza mRNA Vaccine MRT5421 is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Quadrivalent Influenza mRNA Vaccine MRT5421?
Quadrivalent Influenza mRNA Vaccine MRT5421 is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
What development phase is Quadrivalent Influenza mRNA Vaccine MRT5421 in?
Quadrivalent Influenza mRNA Vaccine MRT5421 is in Phase 1.